110 reports of this reaction
3.3% of all BENZALKONIUM CHLORIDE 0.13% reports
#4 most reported adverse reaction
ARTHRALGIA is the #4 most commonly reported adverse reaction for BENZALKONIUM CHLORIDE 0.13%, manufactured by Meijer, Inc.. There are 110 FDA adverse event reports linking BENZALKONIUM CHLORIDE 0.13% to ARTHRALGIA. This represents approximately 3.3% of all 3,369 adverse event reports for this drug.
Patients taking BENZALKONIUM CHLORIDE 0.13% who experience arthralgia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ARTHRALGIA is moderately reported among BENZALKONIUM CHLORIDE 0.13% users, representing a notable but not dominant share of adverse events.
In addition to arthralgia, the following adverse reactions have been reported for BENZALKONIUM CHLORIDE 0.13%:
The following drugs have also been linked to arthralgia in FDA adverse event reports:
ARTHRALGIA has been reported as an adverse event in 110 FDA reports for BENZALKONIUM CHLORIDE 0.13%. This does not prove causation, but indicates an association observed in post-market surveillance data.
ARTHRALGIA accounts for approximately 3.3% of all adverse event reports for BENZALKONIUM CHLORIDE 0.13%, making it a notable side effect.
If you experience arthralgia while taking BENZALKONIUM CHLORIDE 0.13%, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.